12:00 AM
 | 
Jun 25, 2012
 |  BC Week In Review  |  Company News  |  Sales & Marketing

Horizon Pharma, Gruenenthal sales and marketing update

Horizon granted Gruenenthal exclusive rights in Latin America to commercialize Duexis ibuprofen/famotidine. Horizon will receive an undisclosed upfront payment and is eligible for...

Read the full 101 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >